Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative ...

The country's top specialty generics company recently acquired US-based Checkpoint that will further its oncology portfolio ...